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Background: Bacterial lung infections are leading causes of death worldwide. Unfortunately, 
increasing resistance to antibiotics and the inflammation often accompanying these infections are 
leading to poor outcomes despite antibiotic intervention. Complicating treatment further, the 
tree-like branching structure of the lung makes drug delivery to distal sites of infection difficult. 
Our research aims to address these challenges by developing new therapeutics and new tools to 
improve and assess drug delivery, bacterial killing and inflammation. Our therapy combines host 
defense peptides, which have been shown to kill antibiotic-resistant bacteria and down regulate 
inflammation, with a pulmonary vehicle, exogenous surfactant, that can improve distribution in 
the lung.  
 
Methods: We have developed the Wet Bridge Transfer system, a new tool which can rapidly 
assess drug transport, bacterial killing and anti-inflammatory properties of compounds as they 
spread across a surface. 
 
Results: We anticipate that exogenous surfactant will not only increase the transport of host 
defense peptides, but that the mixture will effectively kill antibiotic-resistant bacteria and reduce 
inflammation as it spreads. 
 
Discussion & Conclusion: Utilizing host defense peptides with a spreading agent represents a 
novel approach to treating bacterial lung infections. Additionally, the transfer system offers the 
ability to rapidly screen and examine the next generation of pulmonary therapies.  
 
Interdisciplinary Reflection: This project requires interacting with clinicians treating patients 
with lung infections, biochemists improving the transfer system, and immunologists to 
understand the underlying mechanism of action for our new therapy. This interdisciplinary 
environment is essential to making our novel therapy a clinical reality. 
